Physician profile
David Molina
NPI 1558425538
$10,057.11
in general payments reported to CMS, 2019-2025
13 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $303 · 2021: $407 · 2022: $1,152 · 2023: $1,396 · 2024: $1,918 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,805 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,805.21 |
| Education | $103.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,595.18 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $1,576.48 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $1,498.95 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,393.13 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,126.39 | 2021-2025 | Caplyta |
| Abbvie INC. | $985.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $497.44 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $433.52 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $411.65 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $219.21 | 2025 | Fanapt |
| Indivior INC. | $176.46 | 2019-2024 | Perseris |
| Axsome Therapeutics, INC. | $108.61 | 2023-2025 | Auvelity |
| Braeburn INC. | $34.52 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.